A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers

@article{Addo2002API,
  title={A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers},
  author={Sadiya N Addo and Roger Yates and Alison Laight},
  journal={British Journal of Cancer},
  year={2002},
  volume={87},
  pages={1354 - 1359}
}
While tamoxifen use is associated with clear benefits in the treatment of hormone-sensitive breast cancer, it also exhibits partial oestrogen agonist activity that is associated with adverse events, including endometrial cancer. Fulvestrant (‘Faslodex’) is a new oestrogen receptor antagonist that downregulates the oestrogen receptor and has no known agonist effect. This single-centre, double-blind, randomised, parallel-group trial was conducted to determine the direct effects of fulvestrant on… CONTINUE READING
25 Citations
19 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 19 references

A (2000) The pharmacokinetics

  • SR hardt, M Harrison, Webster
  • 2000

The pharmacokinetics of singledose faslodex ( ICI 182 , 780 ) in postmenopausal breast cancer – relationship with estrogenreceptor down regulation

  • AE Wakeling, M Dukes, J Bowler
  • Proc Am Soc Clin Oncol
  • 2000

Similar Papers

Loading similar papers…